Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer
Allogene Overland Biopharm (Allogene Overland), a joint venture created by Overland Pharmaceuticals and Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the appointment of Shuyuan Yao, Ph.D. as Chief Executive Officer.
- Allogene Overland Biopharm (Allogene Overland), a joint venture created by Overland Pharmaceuticals and Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the appointment of Shuyuan Yao, Ph.D. as Chief Executive Officer.
- Most recently, Dr. Yao served as Chief Scientific Officer, Head of Research & Technology Development of WuXi Advanced Therapies at WuXi AppTec where he led new technology acquisition, development, translation and application.
- Prior to being CSO, Dr. Yao served as WuXi Advanced Therapies China General Manager, establishing a new subsidiary company, ATU China.
- Shuyuan has deep experience in drug development, commercialization and joint venture building, particularly in cell therapy, said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene.